Current Assets
Cash, Cash Equivalents, and Marketable Securities
Neurocrine Biosciences Cash, Cash Equivalents, and Marketable Securities increased by 371.5% to $1.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 398.0%, from $317.3M to $1.58B.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ2 2021
Last reportedQ1 2026May 5, 2026
Metric ID:
cash_equivalents_marketable_securities_totalHistorical Data
7 periods
| Q2 '21 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $245.5M | $458.7M | $317.3M | $401.8M | $349.8M | $335.1M | $1.58B |
| QoQ Change | — | +86.8% | -30.8% | +26.6% | -12.9% | -4.2% | +371.5% |
| YoY Change | — | — | — | — | — | -26.9% | +398.0% |
Range$245.5M – $1.58B
CAGR+246.0%
Avg YoY Growth+185.5%
Median YoY Growth+185.5%
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's cash, cash equivalents, and marketable securities?
- Neurocrine Biosciences (NBIX) reported cash, cash equivalents, and marketable securities of $1.58B in Q1 2026.
- How has Neurocrine Biosciences's cash, cash equivalents, and marketable securities changed year-over-year?
- Neurocrine Biosciences's cash, cash equivalents, and marketable securities increased by 398.0% year-over-year, from $317.3M to $1.58B.